Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -466.18 Million SEK | -13.08% |
| 2022 | -412.26 Million SEK | 19.09% |
| 2021 | -509.53 Million SEK | -16.73% |
| 2020 | -436.51 Million SEK | -1239.9% |
| 2019 | -32.57 Million SEK | 75.33% |
| 2018 | -132.04 Million SEK | -52.14% |
| 2017 | -86.79 Million SEK | -52.51% |
| 2016 | -56.91 Million SEK | -11.56% |
| 2015 | -51.01 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -246.16 Million SEK | -1240.16% |
| 2024 Q2 | -47.47 Million SEK | 80.71% |
| 2023 Q1 | -187.52 Million SEK | -4994.4% |
| 2023 FY | -466.18 Million SEK | -13.08% |
| 2023 Q4 | -18.36 Million SEK | 89.09% |
| 2023 Q3 | -168.35 Million SEK | -83.13% |
| 2023 Q2 | -91.93 Million SEK | 50.98% |
| 2022 Q4 | -3.68 Million SEK | 59.59% |
| 2022 Q2 | -192.42 Million SEK | 7.06% |
| 2022 Q1 | -207.04 Million SEK | 5.53% |
| 2022 FY | -412.26 Million SEK | 19.09% |
| 2022 Q3 | -9.11 Million SEK | 95.27% |
| 2021 Q4 | -219.17 Million SEK | -3498.51% |
| 2021 Q1 | -125.45 Million SEK | 26.39% |
| 2021 Q2 | -159.84 Million SEK | -27.41% |
| 2021 FY | -509.53 Million SEK | -16.73% |
| 2021 Q3 | 6.44 Million SEK | 104.03% |
| 2020 Q1 | -63.71 Million SEK | -176.42% |
| 2020 Q2 | -61.32 Million SEK | 3.75% |
| 2020 FY | -436.51 Million SEK | -1239.9% |
| 2020 Q4 | -170.43 Million SEK | -23.48% |
| 2020 Q3 | -138.02 Million SEK | -125.06% |
| 2019 Q4 | -23.05 Million SEK | 54.03% |
| 2019 Q2 | 83.16 Million SEK | 295.43% |
| 2019 Q3 | -50.13 Million SEK | -160.29% |
| 2019 FY | -32.57 Million SEK | 75.33% |
| 2019 Q1 | -42.55 Million SEK | 3.77% |
| 2018 Q4 | -44.22 Million SEK | -40.83% |
| 2018 FY | -132.04 Million SEK | -52.14% |
| 2018 Q3 | -31.4 Million SEK | -72.69% |
| 2018 Q2 | -18.18 Million SEK | 52.44% |
| 2018 Q1 | -38.23 Million SEK | 5.69% |
| 2017 Q3 | -18.37 Million SEK | -14.08% |
| 2017 Q1 | -11.76 Million SEK | 0.0% |
| 2017 Q2 | -16.11 Million SEK | -37.0% |
| 2017 Q4 | -40.54 Million SEK | -120.6% |
| 2017 FY | -86.79 Million SEK | -52.51% |
| 2016 FY | -56.91 Million SEK | -11.56% |
| 2015 FY | -51.01 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | -2728.792% |
| Amniotics AB (publ) | -30.87 Million SEK | -1410.155% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -3534.121% |
| BioArctic AB (publ) | 229.24 Million SEK | 303.353% |
| Genovis AB (publ.) | 61.5 Million SEK | 858.024% |
| LIDDS AB (publ) | -40.2 Million SEK | -1059.491% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 3930.923% |
| OncoZenge AB (publ) | -15.9 Million SEK | -2831.612% |
| Saniona AB (publ) | -95.81 Million SEK | -386.572% |
| Simris Alg AB (publ) | -37.3 Million SEK | -1149.658% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | -49.927% |
| AcouSort AB (publ) | -17.08 Million SEK | -2627.983% |
| Active Biotech AB (publ) | -45.8 Million SEK | -917.871% |
| Camurus AB (publ) | 431.44 Million SEK | 208.053% |
| Cantargia AB (publ) | -280.02 Million SEK | -66.479% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -2110.35% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -311.377% |
| Mendus AB (publ) | -101.61 Million SEK | -358.758% |
| Kancera AB (publ) | -64.88 Million SEK | -618.435% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 8755.496% |
| Lipum AB (publ) | -37.17 Million SEK | -1153.927% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -3743.874% |
| NextCell Pharma AB | -41.95 Million SEK | -1011.027% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | -20.098% |
| Xintela AB (publ) | -54.08 Million SEK | -761.981% |
| Ziccum AB (publ) | -21.41 Million SEK | -2077.214% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -2742.942% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -2504.822% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -1157.546% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | -159.472% |
| CombiGene AB (publ) | -35.66 Million SEK | -1207.107% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -207.004% |
| Intervacc AB (publ) | -102.85 Million SEK | -353.258% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | -87.535% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -106334.932% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -2721.431% |
| Corline Biomedical AB | -1.8 Million SEK | -25670.315% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | -162.139% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -720.445% |
| Aptahem AB (publ) | -11.11 Million SEK | -4095.001% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -278.803% |
| Fluicell AB (publ) | -26.55 Million SEK | -1655.611% |
| Biovica International AB (publ) | -124.82 Million SEK | -273.477% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -1004.102% |
| Abliva AB (publ) | -95.5 Million SEK | -388.106% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | -42.608% |
| 2cureX AB (publ) | -32.51 Million SEK | -1333.621% |
| I-Tech AB | 20.2 Million SEK | 2407.504% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 43.949% |
| Cyxone AB (publ) | -22.98 Million SEK | -1927.861% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -410.044% |
| Biosergen AB | -27.03 Million SEK | -1624.248% |
| Nanologica AB (publ) | -75.15 Million SEK | -520.282% |
| SynAct Pharma AB | -215.81 Million SEK | -116.016% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -958.213% |
| BioInvent International AB (publ) | -330.3 Million SEK | -41.138% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -1863.96% |
| Oncopeptides AB (publ) | -249.11 Million SEK | -87.139% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -4594.709% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -326.566% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -3891.993% |